Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Anus Neoplasms 2Rectal Neoplasms 1Lymphoma, Mantle-Cell 1HIV Infections 1Digestive System Diseases 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Anal Canal Carcinoma 1Adenomatous Polyposis Coli 1

Interventions

Oxaliplatin 10Fluorouracil 9Capecitabine 8Leucovorin 6Nivolumab 4Cetuximab 4Specimen Handling 3Radiotherapy 3Magnetic Resonance Spectroscopy 3pembrolizumab 2fludarabine 2dostarlimab 2aldesleukin 2Trastuzumab 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiation 2Pemetrexed 2Magnetic Resonance Imaging 2Gemcitabine 2Electrocardiography 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Biopsy 2Bevacizumab 2ulixertinib 1tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Colonoscopy × 30 days × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡